SCHEMBL2437210

SCHEMBL2437210

[CH2]c1ccc(NCCN(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.42
MAPT P10636 2/20 0.41
LMNA P02545 3/20 0.39
HRH3 Q9Y5N1 2/20 0.39
CYP1A2 P05177 1/20 0.39
MAOA P21397 1/20 0.39
CNR1 P21554 1/20 0.39
DRD4 P21917 1/20 0.39
ACHE P22303 1/20 0.39
HRH2 P25021 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
MAPK1 P28482 1/20 0.39
NTSR1 P30989 1/20 0.39
HRH1 P35367 1/20 0.39
DRD3 P35462 1/20 0.39
SCN1A P35498 1/20 0.39
HTR2B P41595 1/20 0.39
SCN7A Q01118 1/20 0.39
SLC6A3 Q01959 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10798745 0.81 TAAR1 (0.52) CYP2C19MAPTSCN9ANOS2
SCHEMBL81430 0.81 MAPT (0.67) CYP2C19MAPTHRH3MAPK1KDM4E
SCHEMBL6318640 0.79 HRH3 (0.46) CYP2C19MAPTLMNAHRH3CYP1A2
SCHEMBL4171220 0.79 ALDH1A1 (0.46) CYP2C19MAPTMAOAMAPK1RAB9A
SCHEMBL8968215 0.79 LMNA (0.57) CYP2C19LMNAHRH3KDM4ERAB9A
SCHEMBL171395 0.78 ALDH1A1 (0.56) CYP2C19MAPTHTR2AHRH1MALT1
SCHEMBL15613318 0.78 HPGD (0.47) CYP2C19MAPTLMNAHRH3CYP1A2
SCHEMBL2460900 0.77 CYP2C19 (0.48) CYP2C19MAPTCYP1A2DRD3MALT1
SCHEMBL10310497 0.76 KCNH2 (0.49) LMNAHRH3KCNH2KDM4E
SCHEMBL250769 0.76 KEAP1 (0.49) CYP2C19MAPTHRH3NCF1NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729060-B2 Macrocyclic polyoxazole compounds and use thereof RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-05-20 US claimed
US-20110230531-A1 THERAPEUTIC COMPOUNDS NIH - DEITR 2011-09-22 US claimed
EP-2183256-A1 THERAPEUTIC COMPOUNDS Rutgers, The State University of New Jersey (US) 2010-05-12 EP claimed
WO-2009018549-A1 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2009-02-05 WO claimed
US-8729060-B2 Macrocyclic polyoxazole compounds and use thereof RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-05-20 US disclosed
US-20110230531-A1 THERAPEUTIC COMPOUNDS NIH - DEITR 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230531-A1 THERAPEUTIC COMPOUNDS MCL1, MKI67, NCL CYP2C19 1753/4885MAPT 3251/4885LMNA 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.